Ovarian Cancer Clinical Trial
Official title:
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
To assess alterations of EGFR& Her2neu expression in primary ovarian high grade serous carcinoma and its correlation with other clinicopathological parameters
Ovarian cancer (OC) is the seventh most common cancer and the fifth cause of cancer death in
women worldwide. The most frequent type is surface epithelial tumors. It is frequently
diagnosed at advanced stages. So, it is referred to as silent killer.
Serous carcinoma is the most common and aggressive type of epithelial ovarian cancer . Serous
carcinomas are currently separated into two completely different subtypes either
histologically or biologically, lowg rade and high grade, based on both degree of nuclear
atypia and the number of mitoses.
Current therapy is based on few traditional prognostic factors, such as tumor stage and
postoperative tumor residual mass. Identification of new molecular markers could help in
significant modification of treatmant improving clinical prognosis The ErbB family of
tyrosine kinase receptors (epidermal growth factor (EGF) receptors) plays a role in the
tumorigenesis of several types of solid tumors. The abnormal activation of these receptors
has been associated with various pathological processes especially cellular transformation .
EGFR is involved in various stages of cancer growth, such as tumor initiation, angiogenesis
and metastasis. Also, it participates by various pathways as a proto-oncogene in several
types of cancers such as gastrointestinal and breast ones. So, it is an attractive target for
oncogenic therapy HER2 protooncogene is involved in the development of many types of human
cancer and is used as therapeutic target. Although the association between HER2 expression
and ovarian cancer has been widely studied, the results are still controversial Therefore, in
the present study we will analyze the expression of both EGFR& Her2neu in an OC tissue
microarray (TMA) by immunohistochemistry, and results were be correlated to other
clinicopathological parameters and prognosis.
Aim of the study:
General aim: To assess alterations of EGFR& Her2neu expression in primary ovarian high grade
serous carcinoma and its correlation with other clinicopathological parameters.
Specific objectives:
1. To measure the frequency of EGFR& Her2neu immunohistochemical expression in ovarian high
grade serous carcinoma.
2. To correlate between expression of EGFR& Her2neu expression and other
clinicopathological parameters of ovarian high grade serous carcinoma
3. To correlate between expression of EGFR& Her2neu expression and prognosis of ovarian
high grade serous carcinoma
Materials:
This cross-sectional study will be done on 54 specimens of ovarian primary high grade serous
carcinoma cases who attended to Oncology Centre, Mansoura University, Mansoura, Egypt since
2012 to the end of 5 years follow up of the last patient The cases will be chosen randomly.
Methods:
1. All clinicopathological data of these cases will be collected such as Tumor size, LN
metastases (N), metastasis (M), ascites, residual tumor, peritoneal deposits,
recurrence, TNM staging & (FIGO) staging system.
2. Prepare hematoxylin & eosin slides to diagnose and assess other histopathological
parameters such as histological type
3. Immunohistochemistry:
Sections 4μm thickness from newly formed tissue microarray blocks will be cut on coated
slides then immunohistochemical staining using antibody against EGFR& Her2neu will be done.
Statistical analysis:
SPSS software version 20 (SPSS Inc., Chicago, IL) will be used for analysis. For nominal
variables, proportions and X2 tests will be applied, whereas for interval variables means,
standard deviations (SD), and T test and ANOVA tests will be applied where appropriate.
Kaplan-Meier method will be used for survival analysis. Chi-square test was used to estimate
the relation between qualitative variables. Mann-Whitney test (non-parametric t test) was
used for not normally distributed quantitative data, for comparison between two groups while,
comparison between three groups was done using Kruskal-Wallis test (non-parametric ANOVA).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |